The Congressionally Directed Medical Research Programs (CDMRP), are supported by funds allocated by Congress for biomedical research in response to the needs of the American people and military. With a FY2018 budget of over $975 million, these funds will go towards supporting R&D efforts in various stages of development. Some research areas covered include Breast Cancer, Parkinson’s, and Multiple Sclerosis as well as additional Peer Reviewed topics covering Alzheimer’s, Cancer, and others.

In this webinar, we discuss the various programs, the process for applying, guidelines, key success components and insight into increasing chances for award.


View Slide Deck

Dr. James B. Phillips of USAMRMC, Department of Defense, shared with the audience the mission of the US Army Medical Research and Material Command and the Medical Technology Enterprise Consortium, discussing opportunities available for partnering and engaging with Industry.

View Slide Deck

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.

In this webinar, FreeMind experts discuss the latest trends at the NIH and the funding opportunities available with respect to medical devices.

View Slide Deck

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.

In this presentation, we provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.

View Slide Deck

In order to maximize your funding potential, all sources of funding must be considered, including the less traditional ones.

The NIH’s R21 mechanism aims to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas the R01 mechanism is more suitable for longer programs of up to 5 years, totaling close to $3,000,000. Other agencies such as the Department of Defense, BARDA, FDA, and NSF also have awards for research in the life sciences.

In this webinar, we share insight into alternatives to the classic SBIR/STTR mechanisms. We will discuss methodology for establishing both responsiveness as well as competitiveness and how to increase chances for award.

View Slide Deck

Every year, US-based non-dilutive sources of funding award billions of dollars towards pre-clinical stage research in the Life Sciences.

Funding is available for pre-clinical research across scientific fields including Infectious Diseases, Oncology, Neurosciences, and many more. These funds come from Institutes within the NIH, such as NIAID, NCI, NINDS, the NSF, the DoD, and private foundations. The NIH alone annually funds over $15B to pre-clinical stage R&D in the life sciences.

In this webinar we discuss the process for applying, guidelines, key success components, and insight into increasing chances for award.

View Slide Deck

NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well.

In this webinar, we discuss key cancer related opportunities, mainly within the National Cancer Institute (NCI), that are available for life science organizations.

View Slide Deck

The National Institute of Allergies and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA, etc., this is a funding force no one in the field can afford to ignore.

In this webinar, we introduce you to Biodefense and Infectious Diseases sources of funding such as NIAID, DTRA, DARPA, US Army, and BARDA, and give examples of current open solicitations. We discuss the process for applying, major challenges, and how to maximize your chances for award.


View Slide Deck